---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123411"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:38:09.011104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tectonic Therapeutic Q3 net loss $17.7M; TX45 Phase 1b enrollment ahead; new HHT candidate TX2100

## Summary
- Net loss of $17.7M for Q3 2024 vs $10.1M a year ago; R&D spend $14.3M (up from $8.1M) on TX45 trials.
- Cash $159.1M as of Sept 30, 2024; runway into mid-2027 covering key readouts and HHT program.
- Phase 1b hemodynamic trial for TX45 enrollment ahead of plan; topline results expected late Q1 2025/early Q2 2025.
- First subject dosed in TX45 APEX Phase 2 trial in Oct 2024; topline data expected 2026.
- TX2100 development candidate selected for HHT (no approved therapy); Phase 1 trial expected Q4 2025/Q1 2026.

## SEC filing metadata
- accession: 0000950170-24-123411
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000095017024123411/0000950170-24-123411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000095017024123411/tecx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123411
- JSON: https://secwatch.observer/filing/0000950170-24-123411.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.